Zertine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zertine

Quick Facts about Zertine

Property Description
Active ingredient Cetirizine Hydrochloride (INN)
Forms Oral Tablets, Capsules, Solution, and Syrup
Pharmacological class H1 Receptor Antagonist (Antihistamine)
Common use Symptomatic relief of allergic reactions
Origin Synthetic compound

What Type of Medicine is Zertine and What is its Composition?

Zertine is a medicinal entity defined by its active ingredient, Cetirizine Hydrochloride, which is classified as a second-generation H1 receptor antagonist. This classification establishes the medicine as a modern antihistamine. It is a synthetic compound, specifically a piperazine derivative and a metabolite of hydroxyzine, designed for effective systemic drug action via oral administration.

Zertine is supplied as a single-ingredient product, available in multiple oral dosage forms, including tablets, capsules, and liquid preparations such as oral solution and syrup, catering to various patient groups. Cetirizine is widely used because it works by blocking histamine. This means the drug is effective at stopping the body’s allergic response at a fundamental chemical level.


How is Zertine Classified in Relation to Allergy Relief?

Zertine is classified as an anti-allergic agent primarily used to provide relief from the symptoms of hypersensitivity reactions. Its core function is to act as a peripheral H1-blocker, where it works through selective antagonism of histamine receptors, preventing the activation that leads to physical symptoms. This role is recognized for its efficacy.

A defining characteristic of Zertine, consistent with its second-generation status, is its non-sedating profile. This functional advantage results from the molecule’s minimal penetration of the blood-brain barrier compared to older antihistamines. This specialized feature ensures effective symptomatic relief while minimizing effects on the central nervous system, making the compound clinically recognized for supporting a patient's normal daily activities.

Regulatory References

  1. NIH MedlinePlus on Cetirizine
  2. NIH MedlinePlus Drug Information

What side effects are possible with Zertine?

Possible side effects and safety information

The safety profile of Zertine (Cetirizine Hydrochloride) is officially documented by regulatory authorities, with potential adverse reactions classified by the frequency observed in clinical use and post-marketing reports.


Adverse Reactions by Frequency

Adverse effects are categorized by incidence according to regulatory standards:

  • Common (affecting up to 1 in 10 patients): These frequently reported effects include somnolence, fatigue, headache, dizziness, and dry mouth.
  • Uncommon (up to 1 in 100): Agitation and paresthesia (abnormal sensation) are listed at this level.
  • Rare (up to 1 in 1,000): Reactions include signs of hypersensitivity, tachycardia (rapid heartbeat), certain psychiatric effects like insomnia and aggression, and reports of abnormal hepatic function.
  • Very Rare (fewer than 1 in 10,000): Severe reactions documented include anaphylactic shock, angioedema (severe swelling), and thrombocytopenia (low platelet count).

Population-Specific Safety Considerations

The official labeling includes cautions for specific patient groups, primarily due to the drug's elimination from the body:

  • Renal and Hepatic Impairment: Clearance of Cetirizine is reduced in individuals with impaired kidney or liver function. The elimination half-life is prolonged, a key factor noted in regulatory pharmacokinetics data.
  • Older Adults: A reduction in drug clearance and a prolonged half-life are also noted for the older adult population.

Safety Constraints and Time-Related Patterns

Official safety documents require caution for use in patients with predisposing factors for urinary retention and in those with epilepsy or a risk of convulsions. The common effect of somnolence has been documented as being dose-related. Additionally, severe, generalized pruritus (itching) has been reported following the discontinuation of long-term use of the medicine.

Overdose and Emergency Response

In case of a suspected overdose of Zertine (Cetirizine Hydrochloride), immediate professional assistance must be sought or a Poison Control Center contacted right away. This urgency is mandated by regulatory bodies due to the potential for severe clinical manifestations.

Overdose is often characterized by a spectrum of Central Nervous System (CNS) effects. Documented presentations include CNS depression, such as somnolence, drowsiness, and fatigue, alongside paradoxical signs of agitation, restlessness, tremor, and confusion. Other physiological signs noted in official labeling include tachycardia (fast heart rate) and gastrointestinal distress, such as diarrhea.

Manifestation Type Examples Documented in Labeling
Severe Outcomes Convulsions, profound tachycardia, cardiorespiratory collapse, and severe anticholinergic symptoms.
Pediatric Note Overdose in children may specifically present with initial restlessness and irritability followed by drowsiness.

The official management of overdose is restricted to symptomatic and supportive treatment by healthcare professionals. Regulatory information consistently states that there is no known specific antidote to the drug, and it cannot be effectively removed by dialysis. This underscores why urgent medical evaluation is required for all overdose scenarios.

Therapeutic Uses of Zertine

What Zertine Treats: Main Uses and Benefits

Zertine (Cetirizine Hydrochloride) is commonly used in situations involving certain distressing symptoms of allergic disease, aiming to moderate manifestations and support patient comfort. It is used in conditions involving episodic or fluctuating symptom patterns and offers assistance in symptom stabilization when discomfort is heightened. The medication is used to relieve symptoms associated with allergies and hives.

This medication helps address symptom clusters that create noticeable physiological strain. This includes symptoms of seasonal and perennial allergic rhinitis, such as frequent sneezing, a runny nose, and persistent itching in the nose, throat, or eyes. It is also relevant for easing the itch, redness, and wheals associated with skin reactions, including chronic idiopathic urticaria.

By offering a non-sedating profile, Zertine may assist with coping more steadily with difficult episodes and supports general well-being during symptomatic phases. This makes it relevant when supportive symptom management is appropriate for both acute flare-ups and long-term management of chronic allergic diseases.


Symptomatic Support Overview

Feature Context of Use
Relief Focus Nasal, ocular, and dermal allergic symptoms
Typical Scenarios Seasonal hay fever, chronic hives (urticaria), insect bite reactions
Patient Benefit Supports stability and general well-being during symptomatic phases

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility to use Zertine (Cetirizine Hydrochloride) is strictly defined by regulatory documentation, focusing on chemical sensitivities, organ function, and age.


Populations for Whom Use is Contraindicated

Use is prohibited for patients with known hypersensitivity to the active ingredient, Cetirizine, or to related chemical compounds such as Hydroxyzine or any Piperazine Derivatives. Additionally, the medicine is contraindicated in patients with severe renal impairment, typically defined as a Creatinine Clearance value of less than 10 mL/min. Specific formulations may also be contraindicated for patients with rare hereditary metabolic issues, such as galactose intolerance or Lapp lactase deficiency.


Restricted and Conditional Eligibility

Zertine is permitted for adults and adolescents 12 years, and for children 6 to 12 years. However, the film-coated tablet is not recommended for children under 6 years old as it prevents proper dose adaptation. Patients with moderate renal impairment require conditional use and a mandatory dose reduction. Caution is recommended for patients with factors predisposing to urinary retention (e.g., prostatic hyperplasia) or convulsions. For pregnancy, use should be avoided or administered only if necessary. Use is also not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information indicates that Zertine (cetirizine) has a low potential for clinically significant drug interactions. However, interactions with specific substance categories and medicines are formally documented.

Documented Interaction Constraints

Interacting Product Category Interaction Mechanism and Constraint
Central Nervous System (CNS) Depressants Pharmacodynamic interaction that may result in additional reductions in alertness and impairment of CNS performance. Concurrent use should be avoided.
Alcohol Pharmacodynamic additive effect; concurrent consumption of alcohol is recommended to be avoided for the same reason as CNS depressants.
Theophylline A pharmacokinetic interaction was observed in a study using 400 mg once daily Theophylline, which resulted in a 16% decrease in the clearance of cetirizine. No alteration to the disposition of Theophylline was found.
Food Food does not affect the extent of absorption but decreases the rate of absorption of cetirizine.

Lack of Observed Interaction

Pharmacokinetic interaction studies conducted with specific medicines, including pseudoephedrine, antipyrine, ketoconazole, erythromycin, and azithromycin, did not observe clinically relevant interactions.

Overall Interaction Profile

The regulatory profile for this product is structured to warn against the additive sedative effects of combining the medicine with alcohol and other CNS depressants, which constitutes the primary interaction restriction. Separately, a specific, clinically observed pharmacokinetic change with Theophylline is documented, which is generally not considered a major constraint but is noted for practitioner awareness. The overall official statements emphasize that most common drug combinations studied do not result in clinically significant interactions.

Mechanism of Action

How Zertine Works: Mechanism of Action

Zertine (cetirizine) operates by influencing the histamine pathway and the cellular inflammatory cascade. Its biological activity is primarily concentrated outside the central nervous system, leading to targeted peripheral effects.


Selective H1 Receptor Antagonism

The drug's primary action is binding to the peripheral H1 histamine receptor. Zertine acts as a selective inverse agonist, stabilizing the receptor in an inactive conformation and effectively blocking the signaling cascade normally triggered by histamine release. This core mechanism modifies early molecular steps, reducing the downstream signaling resulting from high mediator activity in tissues.


Inhibition of Inflammatory Cell Migration

Zertine's secondary activity on inflammation operates independently of its H1 blockade. The mechanism involves restricting the accumulation and activation of key white blood cells, such as eosinophils, at sites of physiological response, particularly during the late-phase cellular reaction. By modifying these cellular processes, the mechanism results in a suppression of heightened physiological responses within targeted pathways.


Predominantly Peripheral Pathway Activity

Zertine's mechanism is characterized by high affinity for peripheral tissues and limited penetration of the blood-brain barrier. Consequently, its action is focused on peripheral biological targets in the airways and blood vessels, resulting in minimal interaction with central nervous system signaling dynamics.

Dosage and Administration Information

How to Use Zertine: Administration Guidelines

Zertine (Cetirizine Hydrochloride) is primarily administered via the oral route, utilizing dosage forms that include tablets, capsules, and liquid preparations. In specific acute care settings, an intravenous (IV) solution may be approved for short-term use in some regions.


Standard Dosing and Frequency

The standard regimen for most adults and children 12 years and older is 10 mg once daily. A lower daily oral dose of 5 mg may be used when symptoms are less severe. The maximum recommended dose in a 24-hour period for an adult is 10 mg. The medicine can be taken with or without food, as its absorption is not reduced by meals, offering flexibility in administration timing.

Population-Specific Use

Dosage adjustments are utilized in patients with impaired renal function due to the drug’s primary reliance on the kidneys for elimination. In these cases, the dose or dosing interval is modified according to the degree of impairment. For older adults, a reduced starting dose of 5 mg is often recommended as a precaution against age-related decline in kidney function.

Pediatric dosing for children aged 6 to 11 years typically involves 5 mg to 10 mg once daily. When using liquid formulations, an accurate measuring device should be used to ensure the correct dose is administered. The intravenous solution, when utilized, is typically administered as an intravenous push over 1 to 2 minutes and is reserved for short-term, acute use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Zertine

This section provides an overview of the types of clinical studies that have been conducted for Zertine (Cetirizine Hydrochloride), focusing on the conditions it has been studied for, the outcomes measured, and what remains uncertain in the research base.


Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Research exploring seasonal allergic rhinitis, often called hay fever, has primarily relied on numerous short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time by comparing the outcomes in subjects receiving Zertine to those receiving an inactive substance (placebo) or another active comparator. Outcomes related to physical discomfort were typically measured using a Total Symptom Score (TSS) and measures of Health-Related Quality of Life (HRQL).

These studies were conducted during periods of increased symptom activity. Findings describe patterns observed in the studies that were generally short-term, lasting only a few weeks. Research explored the time course of its actions, with post-hoc analyses examining outcomes at 12 and 24 hours post-dose to provide insight into short-term changes in morning and evening symptom assessment. The research provides context for understanding symptom patterns, and results reflect the specific conditions and populations studied.


Evidence for Use in Chronic Idiopathic Urticaria (CIU)

Zertine was evaluated in conditions associated with acute or disruptive episodes, such as chronic idiopathic urticaria (CIU), a condition characterized by persistent hives (weals) and itching (pruritus). The evidence for this condition is derived from RCTs and double-blind crossover studies which examined symptom intensity or variability. Primary outcomes related to physical discomfort included the measurement of weal size, weal count, and severity of itching, often combined into scoring systems like the Urticaria Activity Score.

In studies comparing different agents, researchers reported on the assessment of complete symptom cessation (suppression of urticaria) in subjects receiving Cetirizine compared to those receiving placebo. Smaller studies examining higher-than-standard daily amounts reported varied observations, with one double-blind crossover study documenting a reduction in overall urticarial symptoms compared to placebo.


Research Gaps and Uncertainty in the Evidence Base

Evidence highlights what is known, but also what is still uncertain. One significant research limitation is the lack of dedicated, large-scale, long-term efficacy trials to fully characterize outcomes linked to chronic, continuous use over multiple years. Comparative evidence is also lacking in some areas, particularly concerning modern head-to-head trials against the newest generation of second-generation antihistamines for all indications.

Furthermore, findings regarding the utility of doses higher than the standard recommended amount for patients whose chronic urticaria symptoms are not sufficiently assessed remain uncertain. Research describing these specific scenarios involves limited information, and the evidence quality varies across the small number of existing studies, meaning the data are still emerging and should be interpreted with caution. Study results reflect the specific conditions and time constraints under which they were conducted, not personal outcomes or predictions.

Key Studies & References

  1. Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis
  2. Chronic urticaria: off-label doses of cetirizine - NICE Evidence Summary

Frequently Asked Questions (FAQ)

Common questions about Zertine (FAQ)


Q: How quickly can I expect Zertine to start working?

A: According to official regulatory data, the relief of symptoms is generally described as beginning within 20 to 60 minutes after taking the medicine. This time frame reflects how rapidly the active ingredient, Cetirizine, is absorbed into the body.


Q: How long do the effects of Zertine typically last?

A: The medicine is generally described as a once-daily treatment. This standard recommended regimen is consistent with an intended duration of effect that allows for a 24-hour dosing interval. The regulatory information supports this pattern for continuous symptom control.


Q: What are the most commonly reported side effects of Zertine?

A: Official safety information documents adverse reactions by frequency. These frequently reported effects, as documented in official safety information, include somnolence (drowsiness), fatigue, headache, dizziness, and dry mouth. They are defined as affecting up to 1 in 10 patients.


Q: How long can I continue taking Zertine?

A: Regulatory information does not define a maximum duration of use. It acknowledges that the medicine is approved for chronic conditions which may involve long-term administration. A safety warning is documented regarding reports of generalized itching that has occurred following the discontinuation of long-term use.


Q: Is Zertine safe to use during pregnancy, according to official information?

A: Official guidance describes that use during pregnancy should be avoided or administered only if necessary, based on available data. Some international authorities have classified the active ingredient (Cetirizine) as a Pregnancy Category B2. This classification is based on data that have not shown evidence of harm in animal studies.


Q: Can children or teenagers use Zertine?

A: Eligibility is defined by age, typically for adults, adolescents 12 years, and children 6 to 12 years. Official information notes that certain forms, such as the film-coated tablet, are not recommended for children under 6 years old because they prevent the proper dose adaptation required for that age group.


Q: Is Zertine safe for people over the age of 65?

A: Official instructions describe that a reduced starting dose is often used for older adults, typically 5 mg. This is due to a noted age-related reduction in the rate at which the drug is cleared from the body.


Q: Does Zertine interact with sedatives or tranquilizers?

A: Official documents warn that concurrent use of the medicine with Central Nervous System (CNS) depressants, which includes sedatives and tranquilizers, may result in additional reductions in alertness. This combination is noted to potentially cause an impairment of CNS performance.


Q: What are the pregnancy categories or risk descriptions for Zertine from regulatory sources?

A: Some international regulatory bodies have classified the active ingredient as a Pregnancy Category B2. The risk descriptions state that data from animal studies have failed to show evidence of teratogenicity. Official guidance generally describes avoiding use during pregnancy or administering it only if necessary.


Q: What happens if I miss a dose of Zertine?

A: Official regulatory guidance describes an administration pattern where if a dose is missed, it is taken as soon as it is remembered. If the time is close to the next scheduled dose, the missed dose is generally skipped to maintain the standard daily regimen.


Q: Is Zertine available over the counter, or is it prescription-only?

A: The active ingredient in Zertine (Cetirizine) is available as both an over-the-counter (OTC) medicine in certain strengths and formulations, and in specific prescription-only formulations, such as the intravenous solution used in acute care settings.


Q: What is the difference between Zertine and [common comparator drug name, e.g., XYZ]?

A: When compared to similar second-generation antihistamines like Loratadine, research suggests Zertine generally has a faster onset of action. However, regulatory profiles indicate it may be associated with a slightly higher likelihood of drowsiness.


Q: Can Zertine be taken for symptoms other than the main listed uses?

A: Regulatory approval is specific to the symptoms and conditions listed on the official label, which primarily include seasonal allergic rhinitis and chronic idiopathic urticaria. Use for any other symptom is not supported by the official indications and is outside of the conditions specifically studied for regulatory approval.


Q: Is Zertine meant for short-term or long-term use?

A: The medicine is officially approved for both short-term use, such as for the duration of a seasonal allergy, and for chronic conditions like chronic idiopathic urticaria, which may involve long-term administration. Official safety documents include a specific warning regarding discontinuation after long-term treatment.


Q: Can Zertine affect sleep patterns besides causing drowsiness?

A: Official safety documents list somnolence (drowsiness) as a common side effect. Additionally, insomnia (difficulty sleeping) is also noted as a rare adverse reaction to the medicine.


Q: Is it normal to feel a mild headache when starting Zertine?

A: Official regulatory information lists headache as a common adverse reaction to the medicine. This indicates that up to 1 in 10 patients in clinical trials reported experiencing this effect.


Q: Is Zertine habit-forming or addictive?

A: Zertine is not classified as a controlled substance by regulatory authorities. There is no information in official drug labels indicating that the medicine is habit-forming or addictive.


Q: Can Zertine be cut in half, or should it be taken whole?

A: Standard tablet formulations are often described as unscored (meaning they lack a score line) in official product characteristics. Official administration instructions typically describe swallowing the tablet whole.


Q: Does the time of day matter when taking Zertine?

A: The time of day for administration is generally flexible. The drug's absorption is not significantly reduced by food, which allows the medicine to be taken with or without meals, giving flexibility in administration timing.


Q: What is the official dosage strength information for Zertine?

A: Official dosage forms include oral tablets in strengths of 5 mg and 10 mg. It is also available in various liquid preparations, such as solutions or syrups, for specific patient groups.


Q: Is it true that Zertine can cause dry mouth?

A: Yes, official safety information lists dry mouth as a common adverse reaction. This is an effect that was reported by up to 1 in 10 patients in clinical studies.


Q: Can people with certain eye conditions use Zertine?

A: Official regulatory warnings and contraindications for the medicine do not include specific general restrictions related to common eye conditions. The restrictions focus primarily on factors like kidney function or hypersensitivity.


Q: Is Zertine available in different forms, like liquid or tablet?

A: Yes, Zertine is available in various oral dosage forms. These commonly include tablets, capsules, chewable tablets, and liquid preparations such as oral solution or syrup.

How should Zertine be stored and disposed of?

Official Storage and Disposal Requirements

Requirement Area Regulatory Statement
Storage Temperature Store at controlled room temperature, typically 20 C to 25 C (brief excursions permitted up to 30 C).
Environmental Control Protect from light and excessive moisture. Keep containers tightly closed. Do not store above the maximum stated temperature and keep from freezing.
Child Safety Keep out of the reach of children. Store medication in a safe and locked location.
Disposal Protocol Dispose of unused or expired medicine in accordance with local, regional, and national requirements. Do not flush down a toilet or pour into a drain unless specifically instructed by an authority.

Official regulatory documents emphasize that the product must be kept in its original, tightly sealed container to maintain stability and prevent degradation from environmental factors like moisture. Strict temperature control within the designated room temperature range is mandatory to ensure the product remains stable until its expiration date. Disposal must adhere to environmental regulations, preventing the medicine from contaminating water sources, and the product must be kept strictly away from children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zertine found in:

A-Z Index: